M&A News
⇨ Expands immunology portfolio 🧬
⇨ $1.15B upfront and up to $650M potential milestone payments 💰
⇨ Includes lead asset felzartamab, fully human anti-CD38 monoclonal antibody
» demonstrated clinical proof of concept in rare immune-mediated indications
» Planned Ph3 trial
» demonstrated clinical proof of concept in rare immune-mediated indications
» Planned Ph3 trial
![M&A News](https://ussnsimg.moomoo.com/sns_client_feed/70042970/20240523/5475950f57a04df7b3d003b773e089a6.jpg/big?area=100&is_public=true)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment